Astria Therapeutics Inc (NASDAQ: ATXS) kicked off on Monday, up 3.63% from the previous trading day, before settling in for the closing price of $9.65. Over the past 52 weeks, ATXS has traded in a range of $4.43-$16.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded 29.93%. With a float of $48.25 million, this company’s outstanding shares have now reached $56.43 million.
Let’s determine the extent of company efficiency that accounts for 59 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Astria Therapeutics Inc (ATXS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Astria Therapeutics Inc is 14.49%, while institutional ownership is 87.17%. The most recent insider transaction that took place on Apr 01 ’24, was worth 135,939. In this transaction Chief Medical Officer of this company sold 10,000 shares at a rate of $13.59, taking the stock ownership to the 0 shares. Before that another transaction happened on Feb 01 ’24, when Company’s Director bought 2,481,350 for $12.09, making the entire transaction worth $29,999,522. This insider now owns 4,873,721 shares in total.
Astria Therapeutics Inc (ATXS) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.94 earnings per share (EPS), lower than consensus estimate (set at -0.78) by -0.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.93% per share during the next fiscal year.
Astria Therapeutics Inc (NASDAQ: ATXS) Trading Performance Indicators
Take a look at Astria Therapeutics Inc’s (ATXS) current performance indicators. Last quarter, stock had a quick ratio of 22.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.09, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.80 in one year’s time.
Technical Analysis of Astria Therapeutics Inc (ATXS)
Looking closely at Astria Therapeutics Inc (NASDAQ: ATXS), its last 5-days average volume was 0.36 million, which is a drop from its year-to-date volume of 0.61 million. As of the previous 9 days, the stock’s Stochastic %D was 32.36%. Additionally, its Average True Range was 0.72.
During the past 100 days, Astria Therapeutics Inc’s (ATXS) raw stochastic average was set at 32.25%, which indicates a significant decrease from 36.01% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.87% in the past 14 days, which was lower than the 66.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.23, while its 200-day Moving Average is $11.24. However, in the short run, Astria Therapeutics Inc’s stock first resistance to watch stands at $10.15. Second resistance stands at $10.30. The third major resistance level sits at $10.48. If the price goes on to break the first support level at $9.81, it is likely to go to the next support level at $9.62. Now, if the price goes above the second support level, the third support stands at $9.47.
Astria Therapeutics Inc (NASDAQ: ATXS) Key Stats
The company with the Market Capitalisation of 583.07 million has total of 56,434K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -72,890 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -24,530 K.
